… efficacy and safety of first line erlotinib monotherapy in Caucasian patients with locally
advanced or metastatic lung adenocarcinoma carrying activating EGFR mutations based on the …

… , erlotinib, afatinib, and chemotherapy as first-line therapies for patients with advanced NSCLC
harboring EGFR-activating mutations in … population associated with EGFR mutations, but …

… activating mutations of the EGFR gene. The aim of this article is to analyze available data of
EGFR-TKIs in the front-line … of erlotinib in patients harboring an activating EGFR mutation, …

… highest in patients with tumors harboring the activating EGFR gene mutations [36, 43–46]
(… first-line erlotinib or gefitinib with cytotoxic chemotherapy in patients with proven EGFR-mutant …

… such mutations are more prevalent. We report on the long-term results of first-line treatment
with erlotinib … adenocarcinoma of the lung that have a somatic EGFR mutation in their tumor. …

… first phase 3 study to show that patients with EGFR mutation-positive NSCLC who receive
erlotinib … tumours have confirmed EGFR activating mutations should receive erlotinib as first-…

… group similarly identified EGFR mutations that were associated with sensitivity to gefitinib
and erlotinib. Citation15 These EGFR mutations activate the EGFR signaling pathway that …

… (NSCLC) with activating EGFR mutations. We aimed to … of erlotinib compared with
standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation …

… , and activating mutations are often seen in NSCLC [2]. EGFR mutations occur more …
However, studies have shown that EGFR tyrosine kinase inhibitors (TKIs) including erlotinib …

… -small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort
of unselected patients treated with erlotinib, we sought to further describe patient and tumour …